Cross-Sector entity
Of the tracked stories, 3 of 3 also mention Solius Pro, the most common co-covered peer. fda-approval accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. Each carries 2 original sources on average. We currently track 3 Cross-Sector stories that mention Solius Labs, all published on June 18, 2026.
3 verified stories tracked
Last mentioned: Jun 18, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 3 of 3 also mention Solius Pro, the most common co-covered peer. fda-approval accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. Each carries 2 original sources on average. We currently track 3 Cross-Sector stories that mention Solius Labs, all published on June 18, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Solius Labs. Shared-story counts are live from our verified record — not editorial picks.
Bainbridge Island-based startup Solius Labs announces the launch of its FDA-cleared personalized sunlight device, Solius Pro, targeting the growing consumer health and wellness market. The move positions the company at the forefront of a new category of over-the-counter light therapy without prescription.
Solius Labs launches the first OTC FDA-cleared personalized UVB light therapy device, claiming significant health benefits with minimal UV risk. For health consumers, it could offer a convenient way to boost vitamin D and improve mood without sun exposure.
The FDA has established a novel product code for Solius Pro, an over-the-counter UVB light therapy device that claims to deliver biological benefits of sunlight with dramatically reduced risk. The move signals regulatory recognition of personalized home phototherapy as a distinct category.
Source: Business Wire (ca) · Business Wire (ca)
